Abstract:Different inhibitors of the Ca(2+)/calmodulin-stimulated phosphodiesterase 1 family have been described and used for the examination of phosphodiesterase 1 in cellular, organ or animal models. However, the inhibitors described differ in potency and selectivity for the different phosphodiesterase family enzymes, and in part exhibit additional pharmacodynamic actions. In this study, we demonstrate that phosphodiesterase 1C is expressed in the human glioblastoma cell line A172 with regard to mRNA, protein and activity level, and that lower activities of phosphodiesterase 2, phosphodiesterase 3, phosphodiesterase 4 and phosphodiesterase 5 are also present. The identity of the phosphodiesterase 1C activity detected was verified by downregulation of the mRNA and protein through human phosphodiesterase 1C specific small interfering RNA. In addition, the measured K(m) values (cAMP, 1.7 microm; cGMP, 1.3 microm) are characteristic of phosphodiesterase 1C. We demonstrate that treatment with the Ca(2+) ionophore ionomycin increases intracellular Ca(2+) in a concentration-dependent way without affecting cell viability. Under conditions of enhanced intracellular Ca(2+) concentration, a rapid increase in cAMP levels caused by the adenylyl cyclase activator forskolin was abolished, indicating the involvement of Ca(2+)-activated phosphodiesterase 1C. The reduction of forskolin-stimulated cAMP levels was reversed by phosphodiesterase 1 inhibitors in a concentration-dependent way. Using this cellular system, we compared the cellular potency of published phosphodiesterase 1 inhibitors, including 8-methoxymethyl-3-isobutyl-1-methylxanthine, vinpocetine, SCH51866, and two established phosphodiesterase 1 inhibitors developed by Schering-Plough (named compounds 31 and 30). We demonstrate that up to 10 microm 8-methoxymethyl-3-isobutyl-1-methylxanthine and vinpocetine had no effect on the reduction of forskolin-stimulated cAMP levels by ionomycin, whereas the more selective and up to 10 000 times more potent phosphodiesterase 1 inhibitors SCH51866, compound 31 and compound 30 inhibited the ionomycin-induced decline of forskolin-induced cAMP at nanomolar concentrations. Thus, our data indicate that SCH51866 and compounds 31 and 30 are effective phosphodiesterase 1 inhibitors in a cellular context, in contrast to the weakly selective and low-potency phosphodiesterase inhibitors 8-methoxymethyl-3-isobutyl-1-methylxanthine and vinpocetine. A172 cells therefore represent a suitable system in which to study the cellular effect of phosphodiesterase 1 inhibitors. 8-Methoxymethyl-3-isobutyl-1-methylxanthine and vinpocetine seem not to be suitable for the study of phosphodiesterase 1-mediated functions.

Determination of Ca2+/calmodulin-stimulated phosphodiesterase activity in intact cells.

Assays for Cyclic Nucleotide‐Specific Phosphodiesterases (PDEs) in the Central Nervous System (PDE1, PDE2, PDE4, and PDE10)

Identification and characterisation of a human calmodulin-stimulated phosphodiesterase PDE1B1

The Measurement of Cyclic Nucleotide Phosphodiesterase 4 Activities Via the Quantification of Inorganic Phosphate with Malachite Green.

Role of Nuclear Ca2+/calmodulin-stimulated Phosphodiesterase 1A in Vascular Smooth Muscle Cell Growth and Survival.

Direct Determination of Multiple Ligand Interactions with the Extracellular Domain of the Calcium-sensing Receptor*

Unraveling the Interplay of Extracellular Domain Conformational Changes and Parathyroid Hormone Type 1 Receptor Activation in Class B1 G Protein-Coupled Receptors: Integrating Enhanced Sampling Molecular Dynamics Simulations and Markov State Models

Critical Extracellular Ca2+ Dependence of the Binding Between PTH1R and a G-Protein Peptide Revealed by MD Simulations.

Characterization of inhibitors of phosphodiesterase 1C on a human cellular system

Establishment of a Cell Model for Dynamic Monitoring of Intracellular Calcium Concentration and High-Throughput Screening of P2Y2 Regulators

Relationship Between Protein Kinase C and Α1-Adrenoceptor Mediated Ca2+ Influx in Vascular Smooth Muscle Cells

Ca2+/Calmodulin-Stimulated Pde1 Regulates the Beta-Catenin/Tcf Signaling Through Pp2a B56 Gamma Subunit in Proliferating Vascular Smooth Muscle Cells

Functional characterisation of P2 purinoceptors in PC12 cells by measurement of radiolabelled calcium influx

In situ detection of cyclic AMP-phosphodiesterase activity in the heart of Lewis and Sprague-Dawley rats: the effect of restraint stress or amphetamine application

Microplate-based Method to Screen Inhibitors of Isozymes of Cyclic Nucleotide Phosphodiesterase Fused to SUMO

Phosphodiesterases 4B and 4D Differentially Regulate cAMP Signaling in Calcium Handling Microdomains of Mouse Hearts

Molecular Mechanism of Ca2+in the Allosteric Regulation of Human Parathyroid Hormone Receptor-1

Activation of membrane protein-tyrosine phosphatase involving cAMP- and Ca2+/phospholipid-dependent protein kinases

HEK293 cells as a useful model in investigating receptor-operated calcium movement

Differential Integration of Ca2+-Calmodulin Signal in Intact Ventricular Myocytes at Low and High Affinity Ca2+-Calmodulin Targets

Calmodulin-dependent Cyclic Nucleotide Phosphodiesterase in an Experimental Rat Model of Cardiac Ischemia-Reperfusion.